Overview

Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation

Status:
Not yet recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

The aim of this trial is to assess the safety and efficacy of conestat alfa (Ruconest®, Pharming Technologies B.V.) on renal and cerebral ischemic events in patients undergoing TAVI for severe symptomatic aortic stenosis (AS) compared to placebo.

Phase:

Phase 2

Details

Lead Sponsor:

University Hospital, Basel, Switzerland

Collaborators:

Pharming Technologies B.V.
Swiss National Science Foundation

Treatments:

Complement C1 Inhibitor Protein